PMC:3625153 / 7366-8082 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3625153","sourcedb":"PMC","sourceid":"3625153","source_url":"http://www.ncbi.nlm.nih.gov/pmc/3625153","text":"10.1371/journal.pone.0061634.g001 Figure 1 The pharmaceutical FX alters cell signaling endpoints and ABCB mRNA expression in mussel haemocytes under in vivo exposures.\n(A) cAMP content (B) relative PKA activities (C) relative ABCB mRNA expression. All biological endpoints were assessed in haemocytes collected from mussels exposed for 7 days to 0.3 ng/L FX 0.3 ng/L PROP, or to the mixture FX+PROP (0.3 ng/L+0.3 ng/L). A group of control (water) exposed mussels were included in the analysis. Data represent mean ± SEM (N = 5). Different superscripts letters indicate statistically significant differences (p\u003c0.05, one-way ANOVA followed by Bonferroni's test). Basal PKA activity = 0.88±0.07 nmol/min/mg protein.\n\n","divisions":[{"label":"Title","span":{"begin":44,"end":168}}],"tracks":[]}